Herbal/natural products in hypertension for their benefits and disadvantages.
Approximately 70% of the world’s population has been using medicinal herbs as a complementary or alternative medicine that has grown tremendously in both developed and developing countries over the past 20 years (World Health Organization Drugs Strategy 2002–2005). This increase in consumer demand for medicinal plants continues, although scientific data are rare to create safety and efficacy profiles. Its popularity is also related to easy availability, cost-effectiveness leading to better purchasing power, and various factors that perceive that they are generally safe. Herbs are often administered simultaneously with therapeutic drugs for the treatment of major ailments, and herb-drug interactions (HDIs) increase their potential. The main routes proposed for HDIs include cytochrome P450 (CYP450)-mediated inhibition or induction and transport and flow proteins. In our review, we highlighted herbal medicines used for the treatment of various diseases with pharmacokinetic, pharmacodynamic analysis and case reports together with their adverse effects and herb-drug interactions. Therefore, this review can be used as a quick reference database for physicians and healthcare professionals involved in therapy, aiming to maximize clinical outcomes by reducing the negative and toxic effects of plants along with avoiding herb-drug interactions.
- herbal products
- natural products
Herbal products are considered the best choice as complementary medicine in western countries, especially in the United States and Europe. Annual sales of dietary herbal supplements in the United States increase 6.8% year over year. In addition, China and India are the top export countries, while Hong Kong, Japan, the United States, and Germany are the leading importers. The Confederation of Indian Industry (CII) presented that the market size of the Ayurvedic industry in the country is $ 4.4 billion, and the total market size of the Indian health industry is $ 11.8 billion. There has been an increase in demand for “complementary” medicines, including those of plant origin. In addition, there is a significant increase in the self-administration of herbal medicines among the public. In the context of the growing demand and use of herbal medicines for patients and the public, and the subsequent interests of the regulatory authorities, comprehensive research on the safety and effectiveness of herbal products, including the possibility of interactions when simultaneous application is required, should be encouraged. This is because all herbal medicines and dietary supplements are a complex mixture containing multiple active phyto-components that increase the possibility of herb-drug interaction (HDI). Most people who consume herbal products and supplements do not show this to their pharmacist or doctor, thereby increasing the likelihood of HDI being identified and resolved over time. However, data from recent studies show that there is potential for serious interaction between some commonly used herbs/herbal products and commonly used standard medications .
In our review, we highlighted herbal medicines used for the treatment of various diseases with their adverse effects and herb-drug interactions, and stated recommendations for proper use of plants that might prevent possible risks for future incidents.
2. Toxicological risks of plants and herbal products
General risks associated with herbs and/or herbal products include:
Misidentification without assigning with Latin names. Possible causes of misidentification include contamination of cultivated plants with weeds, and resembling plants mistaken for herbs collected in the wild.
Contamination with harmful substances such as heavy metals, polycyclic aromatic hydrocarbons, dioxins, as well as natural toxins or microorganisms.
Interaction with other drugs, such as antagonism or synergism, and medical tests that potentially lead to misdiagnosis.
Adulteration with other medicinal drugs.
Intrinsic toxicity caused by the presence of natural toxins, such as aristolochic acids .
The drug or toxin that causes kidney damage when exposed to a certain level cannot pass the excess urine, and the waste product is what is called nephrotoxicity. In this case, there is an increase in blood electrolytes, such as potassium and magnesium. This situation begins temporarily but can be serious if it is not detected before. Blood urea nitrogen (BUN) test and creatinine levels in the blood are two simple tests called as kidney function tests used to detect the nephrotoxicity. For healthy individuals, the normal levels of BUN and creatinine are between 10–25 mg/dl and 0.7–1.4 mg/dl, respectively. The following factors may increase these values:
Obstruction of blood flow to or from kidney caused by a tumor, stone, or irregular heart rhythms.
Nephritis or urinary tract infection.
The aftermath of diseases such as diabetic neuropathy, congestive heart failure, and enlarged prostate gland in man.
Radiocontrast dye injected intravenously to improve visibility.
Drug toxicity with some chemotherapeutics (carboplatin, carmustine, cisplatin, methotrexate, and mitomycin) and biological therapeutic agents (interleukin-2 and interferon-alpha), antibiotics (amphotericin B, gentamicin, and vancomycin), NSAIDs (ibuprofen), diuretics (furosemide), and ACE inhibitors (captopril, benazepril, and enalapril).
Nephrotoxicity after taking herbal medicine.
The cause of nephrotoxicity after taking herbal medicine may be the addition of toxins during careless preparation, addition of adulterants, heavy metals, and some pharmaceutical products intentionally reducing costs or increasing effectiveness .
About 50 plants were related to kidney damage case reports published in PubMed in the last 50+ years (from 1966 to May 2016). Herbs include
The causes of liver damage are both hepatocellular and extracellular mechanisms such as hepatocyte disruption, transport protein disruption, T-cell activation, hepatocyte apoptosis, disruption of mitochondria, injury of bile duct, drug toxicity, and drug interaction .
When hepatotoxicity caused by herbal drug intake is discussed, case rates are often reported. The severity of toxicity varies greatly between mild hepatitis and acute liver failure. The scoring system for allopathic drugs can be evaluated, but not suitable for herbal medicines and needs validation. Many Ayurvedic and Chinese herbal medicines are reported to cause hepatotoxicity. The main hepatotoxic herbs are
Cardiotoxicity is a term used for damage to the heart or change heart functions. It is a condition where there is a change in the electrophysiological function of the heart or damage to the heart muscle, weakening the heart and causing poor blood circulation. This can be detected by symptoms such as dry, unproductive cough; inflammation in the ankles, hands, feet, and neck vessels; irregular heartbeat; tachycardia; cardiomegaly; weakness; dizziness; etc. .
Herbal drugs that have a direct effect on the heart include medicine prepared from plants such as
2.3.1 Potential precautions of plants on hypertension
Herbal products are widely used in the general population and many are encouraged for the natural treatment of hypertension. Patients with hypertension often prefer to use these products in addition to or instead of pharmacological antihypertensive agents. Due to the frequent use of herbal products, both consumers and healthcare providers should be aware of the major issues surrounding these products and factors affecting both effectiveness and damages (Table 1) .
|Herbal/natural products for evidence of benefit||Herbs/herbal products for evidence of harm||Causes|
|Coenzyme Q10||Cardiac effects, hypertension, palpitations, tachycardia, stroke, seizures|
|Fish oil||Blood pressure increases occur in healthy people|
|Hypertension, tachycardia, palpitations|
|Vitamin C||Mineralocorticoid excess syndrome, subsequent hypertension|
The physical brain damage occurred by exposure to neurotoxin is stated as neurotoxicity. Neurotoxin is a substance that causes changes in the nervous system activity by disrupting or killing neurons. Neurotoxicity symptoms are generally emotional disorders, visual impairment, extremity failing, sexual dysfunction, headache, and behavioral alteration.
2.4.1 Psychiatric and neurological adverse effects
Psychiatric and neurological patients often try herbal medicines assuming they are safe. Numerous case reports include various adverse events such as cerebral arteritis, cerebral edema, delirium, coma, confusion, encephalopathy, hallucinations, intracerebral hemorrhage and other cerebrovascular accidents, movement disorders, mood disorders, muscle weakness, paresthesia, and seizures. Some deaths have been recorded. Misuse is caused by toxicity of herbal ingredients, contamination and adulteration, and herb-drug interactions  (Table 2).
|Herbs||Adverse effects||Potential drug interactions|
|Insomnia, vaginal bleeding, mastalgia, mania||Phenelzine, hypoglycemic drugs|
|Headache, GI symptoms, hangover||Other CNS depressants|
|Ataxia, blurred vision, disorientation, other cholinergic signs||Other anti-cholinergic agents|
|Mineral corticoid effects||Antihypertensives, corticosteroids, digoxin|
|Nausea, drowsiness, ventricular tachycardia||Other CNS depressants|
|GI symptoms and cramps, confusion, hallucination, liver failure||Inhibitors of cytochrome P-450 system|
|GI symptoms, restlessness, allergies, hepatitis||Other CNS depressants|
|Anxiety, confusion, insomnia, psychosis||Other CNS-stimulants, beta-blockers, MAO-inhibitors, phenothiazines, theophylline|
|GI symptoms, allergies, headache, dizziness, bleeding||Anticoagulants|
|Dryness of mouth, nausea, GI symptoms, leukopenia||Not known|
|Cyanosis, delirium, GI symptoms||Not known|
|GI symptoms, allergies, fatigue, anxiety||Serotonin reuptake inhibitors, hepatic enzyme inducer|
|Acidosis, bradycardia, diarrhea, hypokalemia||Antiarrhythmics, antihypertensives|
2.5 Skin toxicity
Cutaneous toxicity is a term used for a pronounced negative effect such as skin irritation, inflammation, or rashes of the epidermal growth factor receptor caused by exposure to a plant, chemical, or environmental factor. Skin consisting of a layer of dead cells and several layers of living cells is the largest organ and a defensive barrier of the body. When irritant influences into the skin, the living cells react due to cause inflammation or dermatitis. Inflammation consists of four parts including redness, pain, heat, and swelling. Skin toxicity can be detected easily as the reaction is observed immediately. The most common sources of skin toxicity are food and cosmetics, and others are medicated lotions, balms, creams, inhalers, and essential oils. Various herbal ingredients are available in all the cosmetics and medicinal products mentioned above. Types of skin sensitization reactions include:
There is another type of phototoxic photosensitization caused by contact with some plants. Such a reaction occurs when a photoactive chemical produced by plants touches the skin, and is absorbed and activated by sunlight. Intensity varies depending on time and exposure amount.
3. Contamination of herbal medicines by tropane alkaloids
Tropane alkaloids that have been known as toxic and hallucinogenic are mainly seen in Solanaceae plants (
4. Herb-drug interactions with the plants including furanocoumarins
Naturally occurring furanocoumarins are abundant in citrus fruits, vegetables, and medicinal herbs from the Apiaceae, Fabaceae, and Rutaceae families. Grapefruit-drug interactions were first discovered by chance in 1989 where 5-fold higher felodipine plasma concentrations were observed. Consumption of grapefruit juice has increased the oral bioavailability of various drugs, including calcium channel blockers (e.g., felodipine, nifedipine), HMG-CoA reductase inhibitors (simvastatin, lovastatin), benzodiazepines (midazolam, triazolam), antihistamines (terfenadines), and immunosuppressants (cyclosporine). In addition, phototoxicity developing with furanocoumarins occurs as a result of exposure to sunlight, following contact with the plant. Phototoxicity results in acute dermatitis, sometimes blisters, and vesicles. In many cases, prolonged hyperpigmentation is observed. Photochemotherapy for a long time with furanocoumarins can also cause cancer (skin and liver) .
5. Toxicity of pyrrolizidine alkaloids
Pyrrolizidine alkaloids (PAs) are common components of hundreds of plant species of unrelated botanical families scattered across many geographical regions of the world. In more than 6000 plants belonging to three large plant families, Asteraceae, Boraginaceae, and Fabaceae, above 660 PAs and PA
6. Adverse effects of anthraquinone derivatives
Anthraquinone derivatives with a laxative effect appear in a number of plants:
Many reports on the adulteration of herbal products with synthetic drugs have been systematically reviewed and published with case reports. The list of herbal products and adulterants produced in this way is quite impressive and caused serious side effects (Table 3). A case with the latest herbal product adulterated is related to a 56-year-old man from Indonesia. While visiting Australia, he was hospitalized in a mixed condition arising from hypoglycemia. He insisted that type II diabetes was controlled only by diet. However, despite dextrose infusions, glucose levels do not normalize. It was eventually discovered that he also received a TCM “Zhen Qi” from Malaysia. It was analyzed and shown to contain glibenclamide. Like that, in some cases, patients were severely damaged. Examples of serious side effects include agranulocytosis, Cushing’s syndrome, coma, over-anticoagulation, gastrointestinal bleeding, arrhythmias, and various skin lesions. Due to the adulteration of herbal products with synthetic drugs, adequate and necessary procedures should be applied, and whole herbal products should be analyzed before marketing .
8. Heavy metal contaminations
It is possible to come across heavy metals such as cadmium, cobalt, copper, iron, manganese, nickel, lead, zinc, and mercury in concentrations that are not produced within the framework of certain rules, especially the traditional Chinese herbal preparations. This contamination is probably caused by contamination during drying and preservation. With severe complications that may occur, these types of products are unlikely to cause adverse health effects, even if they are not consumed in large quantities for long periods of time .
9. Herb-drug interactions (HDI)
There are no molecules in nature that have no effect. Therefore, this diversity increases the variety of products while increasing the probability of interaction. If the effect of a drug is changed qualitatively or quantitatively by another substance (herbal medicine/product/ingredient), there is an interaction between these two drugs. It can be said as a rule that two drugs should be present at the same time in the body, especially in the place of interaction, for interaction to occur. But sometimes, if the drug causes a permanent effect on the body, interaction can occur even if such a drug is not found in the body. Interaction is sometimes deliberately created to increase the therapeutic effect of one drug with another drug or to reduce its side effects, which are useful interactions. In other cases, the interaction may occur undesirably as a result of unauthorized use of medicines or when the patient is starting treatment with a particular medication. Sometimes, unpredictable interactions due to new drugs may occur. Drug-related as well as disease-related factors (patient’s age, gender, genetic characteristics, pathological condition), such as the posology and method of administration, pharmacokinetic, pharmacodynamic, and therapeutic properties of the drug may cause interactions between medicines and herbal medicines (Figure 1) .
It is observed that the use of herbal medicines/herbal products is more common in the geriatric group aged 65 and over, and the use in women in this adult population is higher than in men. Herbs/herbal products/drug interaction is higher in patients using drugs with narrow therapeutic index. Information on herbs-herbal products/drug/component interactions is based on
Pharmacodynamic interactions occur when one drug changes the effect of another, that is, an effect opposite or in the same direction, chemically combined with it. That is, if the herbal medicine and drug affect the same receptor or the same site, interaction occurs and a synergic or antagonistic effect may occur. While the effect of the drug increases as a result of the additive effect, the effect of the drug decreases or disappears as a result of the antagonistic effect. The concentration of the drug in body fluids, plasma, is not changed by the second drug. Although most of the drug metabolism is carried out in the liver with cytochrome P450 enzymes, the metabolism of some drugs can be in the blood, kidney, skin, and intestine. Approximately 50 different cytochrome P450 enzymes have been identified. However, a small portion of these enzymes play a role in drug metabolism. Herbal drug-drug interactions are generally pharmacokinetic-type interactions that result from enzyme inhibition or induction .
The following are the evaluation parameters used to determine the probability of herb-drug interactions:
Adequate patient history.
Concurrent diseases, conditions, or other drugs associated with adverse events.
Concomitant medications are documented.
The description of the interactors is sufficient.
Clearly, alternative explanations are excluded.
Chronology is complete.
The time sequence of drug administration to adverse event is reasonable.
An adverse event has been sufficiently defined.
The event ends after stopping the medicine.
The activity repeats upon challenge again .
9.1. Herb-drug interactions in the treatment of cardiovascular disorders (CVDs)
In 2015, an estimated 422.7 million cases of cardiovascular disease (CVD) and 17.92 million CVD deaths were reported worldwide. And most people in the world still prefer complementary and alternative medicine (CAM) as their first treatment option. The consumption of over-the-counter CAM consumption increases the risk of HDI, which endangers the effective medical management of CVD. In cardiac therapy, the narrow therapeutic drug window and a wide range of cardiac drugs available for treatment are also a major cause of concern for HDI. People with chronic diseases often use CAM therapies inappropriately to manage their condition and thereby increase the potential or possibility of HDI formation .
This section of our review focuses on plants reported in the literature by preclinical or clinical studies (rats or humans) or cardiovascular drugs with appropriate case reports. These herbs are reported to affect the pharmacokinetics of some cardiovascular drugs through a variety of HDI mechanisms. Reported HDI studies of some plants commonly used for the treatment of CVDs are summarized in Table 4 .
|Herbs||Interacting drugs||CYP, P-gp induction/inhibition|
|Verapamil, digoxin, propranolol||CYP3A4, CYP2D6 and CYP1A2 (inhibition)|
|Losartan, rosuvastatin, warfarin, clopidogrel||CYP3A4, CYP1A2, CYP2B6, CYP2C19, CYP2C9 (inhibition)|
|Talinolol||P-gp induction, intestinal P-gp in subjects with ABCB1 C3435T genotype inhibition|
|Amiodarone, valsartan||CYP1A (induction), CYP2C9 (inhibition)|
|Nifedipine, phenprocoumon||CYP2C9 (potent inhibition) CYP2C19, CYP3A4 (moderate inhibition)|
|Warfarin||CYP3A4 (induction) CYP1A2, CYP2C9, CYP1E1, CYP2C6, CYP2C11 (inhibition)|
|Atorvastatin, cilostazol||CYP2C9, CYP3A4 and CYP2D6 (inhibition) P-gp induction|
|Diltiazem, cilostazol||CYP1A2, CYP3A, and CYP2C9 (P-gp inhibition inhibition) CYP2C19 (induction)|
|Talinolol||Intestinal P-gp inhibition|
|Atorvastatin, simvastatin, lovastatin||CYP2B6, CYP2C9, CYP2C19 (inhibition) CYP3A4 (induction)|
|Warfarin||CYP3A4 (induction), CYP2C11 (inhibition)|
|Warfarin||CYP 1A2 (induction) CYP2D6, CYP3A4, and OATs (inhibition)|
|Atorvastatin||Intestinal CYP3A4 inhibition|
|Lovastatin||Intestinal CYP3A4 inhibition|
|Simvastatin||Intestinal CYP3A4 inhibition|
|Phenprocoumon||CYP2C9 induction, CYY3A4 induction|
|Atorvastatin||CYP3A4 induction, P-gp induction|
|Pravastatin||Intestinal CYP3A4 inhibition|
|Simvastatin||CYP3A4 induction, P-gp induction|
|Digoxin||P-gp induction, digoxin uptake inhibition|
|Nadolol||Intestinal OATP1A2 inhibition|
|Rosuvastatin||Intestinal OATP1A2/OATB2P inhibition|
|Atenolol||Unknown (possible mediated by OATP function and modulation of intestinal drug uptake)|
9.2 Herb-drug interactions with chemotherapeutic drugs
One of the most important risks associated with the combined use of herbal products and chemotherapeutic agents is herb-drug interactions. Patients with chronic illnesses who use more than one drug have a higher risk. Herb-drug interaction is undesirable in the treatment of cancer due to the perpendicular dose-effect relationship and toxicity of chemotherapeutic agents. The most common mechanism of herb-drug interaction is herbal mediated inhibition and/or stimulation of drug-metabolizing enzymes and/or transport proteins that lead to changes in the pharmacokinetic order of the victim drug. This focus on clinically significant herb-drug interaction should attract public attention, including practitioners, researchers, and cancer chemotherapy consumers (Table 5) .
|Herbs||Cancer drugs||Study type||Results|
|Etoposide||Case report||It was found that taking echinacea with etoposide rarely reduced platelet (16 × 103/L) compared to etoposide alone (44 × 103/L)|
|Docetaxel||Prospective study in 10 cancer patients||Echinacea did not cause a significant change in the pharmacokinetics of docetaxel|
|Docetaxel||Prospective, patient controlled, pharmacokinetic||Garlic was found to reduce docetaxel clearance. Although this reduction is not statistically significant, it can potentially increase side effects due to docetaxel accumulation|
|Imatinib||Case report||After receiving ginseng in patients receiving imatinib for 7 years, hepatotoxicity symptoms began to appear. Hepatotoxicity improved upon discontinuation of ginseng|
|Docetaxel||Case report||Grapefruit juice has been found to reduce the clearance of docetaxel, while increasing the AUC and terminal half-life of docetaxel|
|Nilotinib||Open label, randomized, 2 period crossover||It was found that grapefruit juice increased the AUC and the peak concentration of nilotinib, but did not affect the elimination half-life|
|Irinotecan||Pharmacokinetic study||It has been found that milk thistle causes a statistically insignificant decrease in irinotecan clearance, which is unlikely to cause a clinical effect|
|Docetaxel||Pharmacokinetic study||St John’s wort was found to cause a significant decrease in plasma docetaxel concentration|
|Irinotecan||Unblinded, randomized crossover study||St John’s wort caused a 42% reduction in plasma concentrations of the active metabolite (SN-38)|
|Imatinib||Open-label, crossover pharmacokinetic study||St John’s wort reduced the plasma concentration of imatinib by 32% and reduced the half-life of imatinib by 21%|
|2-period, open-label, fixed sequence study||St John’s wort increased the imatinib clearance by 43% and decreased the plasma concentration by 30%|
9.3 Herb-drug interactions with attention-deficit/hyperactivity disorder (ADHD) medication
In some pediatric patients with attention deficit/hyperactivity disorder (ADHD), natural products such as herbal medicines are used. Although herbal remedies are thought to be safe when used appropriately, they may contain active ingredients that can interact with concurrently used medications and can lead to adverse events for natural products-drug interactions (Table 6) .
|Strattera||An 8-year-old male patient with a history of ADHD, astigmatism, behavioral disorder, learning disorder, and asthma was using 25 mg Strattera for ADHD from October 2008 to September 2009. From May 2001 to November 2010, he was taking 85 mg of |
|Ritalin||A 7-year-old female was treated with Ritalin 10 mg/day orally for ADHD from October 2001. The patient has also been taking Efalex evening primrose oil since 2001. On March 7, 2002, she developed a tic including her both arms. It has become more complex. Ritalin was discontinued on March 7, 2002. There was an improvement in head, arm, neck, and leg movements after cessation, but movements were still present. There was no history of tic or movement disorders in the family. Before the tics, the patient had a nightmare for 1 week. She also had a skin rash and dry skin in her mouth. The case was considered medically significant|
|Concerta||An 11-year-old male was using 36 mg of methylphenidate per day for ADHD for several years. The patient was also taking evening primrose oil for an unknown indication and duration. There was a history of moderate to severe developmental delay and slow learning. Methylphenidate was exhausted on December 30, 2002 and was brought to emergency with severe torticollis, rolling arm movements, lip chewing, and pharyngitis. On January 2, 2003, he presented to the pediatrician with the same symptoms and speech disorder, did not eat or drink, and was hospitalized. Torticollis improved with intravenous cetirizine hydrochloride. The patient was also diagnosed with pharyngeal abscess|
|Concerta||A 17-year-old female with a history of ADHD and depression was treated with methylphenidate for about a year. Concurrent medication included St. John’s wort. The patient experienced psychotic symptoms on an unknown day. The patient saw and heard things that were not there and disturbed at night. The result was considered medically significant|
|Ritalin||A 15-year-old male started 20 mg oral/day Ritalin for ADHD in 1998 and tolerated it well. He suffered a period of sadness from June 1, 2001, and he took St. John’s wort (five drops) orally to treat his depression. A few hours later he presented agitation, unexplained crying, depression-changing aggression, and difficulty concentrating. On June 6, 2001, St. John’s wort ceased and these symptoms subsided. Three weeks later, St. John’s wort was restarted and the same symptoms appeared. St John’s wort was quitted and symptoms were relieved again. The reaction was considered medically significant|
9.4 Herb-drug interactions (HDI) with chronic kidney disease (CKD) medication
Chronic kidney disease (CKD) is defined as abnormalities in kidney structure or function that have been going on for more than 3 months, with adverse health consequences. The prevalence of CKD is estimated to be 8–16% worldwide. Most importantly, patients with CKD are advised to avoid over-the-counter products and herbal medicines according to the Kidney Disease Improving Global Outcome (KDIGO) guidelines. However, several studies have revealed that many patients with CKD have returned to complementary and alternative medicine (CAM) for a desperate treatment. The consumption of unregistered herbal products is more common today because these products can be easily purchased from on-line media, street markets, or stores. It is an alarming trend as it may be linked to an increase in the number of patients with liver and kidney failure in public hospitals. In addition, patients with CKD are at higher risk of developing cardiovascular disease. Most of them are prescribed with antiplatelet and anticoagulants. Anti-platelets and anticoagulants may interact with synergistic or additives with CAM products, which can cause blood-thinning effects that may later cause excessive bleeding (Table 7) .
|Dosage form/doses associated with safety concerns||Safety concerns|
|Crude and standardized ||It may hypoglycemic effect and can cause hypertension, as well as may interact with anticoagulants|
|Standardized ||It may interact with anticoagulants and can cause a severe allergic reaction|
|Cinnamon extract||It may have hypoglycemic effect and may cause worsen liver conditions|
|Dried root, liquid extract, doses >10 g/day||It may interact with anticoagulants|
|Fresh garlic, dried powder (>7 g/day), higher doses than usual dietary intake||It may interact with anticoagulants, antihypertensive, anti-hyperlipidemic, and hydrochlorothiazide|
|It may interact with hepatic metabolizing enzymes, anticoagulant, antiplatelet, anti-hyperglycemic, barbiturates|
|Bitter melon tea, bitter melon extract administered intravenously and intraperitoneally, high-dose bitter melon seed||It may hypoglycemic effect and may interact with hypoglycemic agents, death in children|
|Pomegranate juice, pomegranate extract||It may possibly interact with anticoagulants|
|Dong Quai extract (tablet), dose: 565 mg (1–2 tab/day) for 4 weeks||It may increase the risk of bleeding, increase cancer risk, as well as may interact with anticoagulants, antiplatelet, estrogen (augments the effect of estrogen)|
|Alfalfa seed products||It may cause autoimmune diseases (SLE, multiple sclerosis, rheumatoid arthritis), photosensitivity, estrogen-like and hypoglycemic effects, and may interact with immunosuppressants, warfarin, oral contraceptives, estrogen conjugates, oral hypoglycemic agents, iron, vitamin|
|Fenugreek seeds, fenugreek seed powder (>5 g)||It may have a hypoglycemic and estrogen-like effects|
|Tea (high dose >600 mg/day or 2.25–4.5 L/day)||It may cause liver problems, and may interact with nadolol (beta-blocker), diuretics|
|Noni juice, dose >400 mL||It may cause liver toxicity, and contains high potassium|
|A product containing blue-green algae||It may increase the risk of bleeding, may interact with immunosuppressant, antiplatelet, anticoagulants, NSAIDs, other herbs that reduce blood clotting (e.g., ginseng, garlic, ginkgo)|
9.5 Herb-drug interactions with menopause medication
Herbal remedies are popular among women to relieve menopausal symptoms such as hot flashes, energy loss, depression, joint pain, and insomnia. As recently reviewed, a variety of herbs used to treat menopausal symptoms can cause herb-drug interactions (Table 8) .
|Increase the activity of antihypertensive agents|
|Inhibit platelet aggregation and increase risk of bleeding if co-medicated with anticoagulants|
|Potentially interacts with anti-inflammatory drugs, corticosteroids, beta-blockers, antipsychotics and anticoagulants|
|Increase the activity of CYP3A4 and alters the metabolism of drugs|
|Interact with CNS depressants, antipsychotics, hormones and CYP-metabolized drugs|
10. Herb-micronutrient interactions
The ability of some foods to reduce or increase the absorption of various vitamins and minerals has been known for years. Almost half of the population regularly uses some herbal products as a dietary supplement, along with the vitamin and mineral supplements. The use of these products has increased significantly over the past two decades, and a number of clinically relevant herbal drug interactions have been identified during this time. Therefore, it is likely that the mechanisms underlying many herb-drug interactions may also affect micronutrient absorption, distribution, metabolism, and excretion. Not taking these eccentricities into account can negatively affect the outcome and interpretation of any advanced herb-micronutrient interaction studies  (Table 9).
|Phytochemicals||Micronutrient affected||Effect and interaction mechanisms|
|Plant polyphenols (PPs) (tea catechins, phloretin, quercetin)||Iron||PPs reduce absorption through complexation|
|Folate, ascorbate||PPs reduce absorption through uptake transporter inhibition|
|Silymarins||Iron||They reduce absorption through complexation|
|Phytic acid||Calcium, iron, zinc||It reduces absorption through complexation|
|Hyperforin (St. John’s wort)||Vitamin D3||It enhances plasma clearance through induction of CYP3A4 metabolism|
11. Databases setup for plants/dietary supplements
The Integrative Medicine Service at Memorial Sloan Kettering Cancer Center has developed About Herbs (www.aboutherbs.com), which provides research information, including alleged uses, side effects, and herb-drug interactions for about 284 dietary supplements. Using Google Analytics, they have detected that more than 26,317,000 hits have been recorded since November 2002. According to these data, top 10 plant and/or dietary supplements in 2018 were chaga mushrooms, turmeric, ashwagandha, reishi mushroom, graviola, Active Hexose-Correlated Compound, boswellia, dandelion, green tea, and
|Common name||Scientific name of the plants/dietary supplements||Key interaction and concerns||Avoid in|
|Chaga||High in oxalates|
Diabetic patients on treatment (acarbose)
|Turmeric||High in oxalates|
|Ashwagandha||Increase testosterone levels in men||Prostate cancer|
|Graviola||Antihyperglycemic agents||Diabetic patients on treatment|
|AHCC||CYP2D6 enzyme inducer||Breast cancer patients on doxorubicin, zofran, and aromatase inhibitor (letrozole)|
|Hormone-sensitive breast cancer|
|Green tea||High doses or taken on an empty stomach can cause liver toxicity Bortezomib||Elevated liver function tests|
|Turkey tail mushroom||Unknown||Patients on immunosuppressants (in theory)|
|Plants||Effect and usage||Drugs||Interactions|
|Antihypertensive, antithrombotic, fibrinolytic, antimicrobial, antidiabetic and lipid-lowering properties ||Anticoagulant||May lead to increased anticoagulation effect of warfarin and may increase the risk of bleeding [21, 22, 23]|
|Antiretroviral (saquinavir)||May decrease the plasma level of protease inhibitor saquinavir [24, 25]|
|Antidiabetic (metformin, chlorpropamide)||May occur greater reduction in blood glucose level [26, 27]|
|Paracetamol (acetaminophen)||May change some pharmacokinetic variables of paracetamol |
|Laxative antidiabetic ||Corticosteroids and potassium-depleting diuretics||Laxative and potassium lowering effect may result in hypokalemia [29, 30]|
|Cardiac glycosides and antiarrhythmic drugs||May enhance the hypokalemia-related arrhythmia [29, 30]|
|Antidiabetics||Because of the glucose-lowering effects, diabetic patients should be careful when combining with an antidiabetic agent |
|Laxative ||Corticosteroids and potassium-depleting diuretics||May lead to hypokalemia, since senna can cause excessive water and potassium loss, theoretically |
|Digitalis glycosides||Risk of digitalis toxicity due to hypokalemic effect of senna, theoretically |
|As immunostimulant and in treatment of upper respiratory tract infections ||Anabolic steroids, amiodarone (antiaritmic), methotrexate (chemotherapy agent-immunosuppressant), ketoconazole (antifungal), and acetaminophen||The risk of hepatoxicity by concomitant usage of potentially hepatoxic |
|Immunosuppressants||Might decrease the effects of immunosuppressants, theoretically |
|Midazolam (benzodiazepine)||May increase oral bioavailability of midazolam or |
|To improve cognitive functions, cerebrovascular disorders and vertigo ||Phenobarbital||Reduces the therapeutic potency of phenobarbital |
|Ibuprofen (NSAID)||May cause fatal intracerebral bleeding |
|Anticoagulant (warfarin) and antiplatelet (aspirin) drugs||Possible additive inhibition on platelet aggregation [37, 38]|
|Thiazide diuretic (not specified in the original paper)||Further increase in blood pressure |
|Nicardipine (a calcium channel blocker)||Decreasing the hypotensive activity of drugs |
|Nifedipine, diltiazem (calcium channel blockers) and talinolol (β-blocker)||Possible increased antihypertensive activity resulting from high bioavailability [41, 42, 43, 44]|
|Cyclosporine||Decreased bioavailability of drug |
|Midazolam (benzodiazepine)||Decreased bioavailability of drug |
|Propranolol (β-blocker)||Decreased the plasma concentrations of propranolol |
|Theophylline||Less efficacy with |
|Omeprazole (proton pump inhibitor)||May induce the metabolism, and reduce the effect of omeprazole |
|Tolbutamide (an antidiabetic drug)||May increase or decrease the hypoglycemic effect of tolbutamide |
|Amikacin (aminoglycoside)||Amikacin ototoxicity may enhance |
|Expectorant, antispasmodic and anti-inflammatory properties and in treatment of peptic and duodenal ulcers ||Prednisolone (corticosteroid)||Glycyrrhizin increases the plasma concentrations and potentiates pharmacological effects of prednisolone [52, 53]|
|Hydrocortisone (corticosteroid)||Glycyrrhetinic acid potentiates the activity the topical cutaneous vasoconstrictor effect |
|Dexamethasone (corticosteroid)||Dexamethasone induces the mineralocorticoid effects of glycyrrhizin |
|Antihypertensives||Mineralocorticoid effects (sodium and water retention and hypokalemia) of plant reduce the efficacy of the drugs that use to lower blood pressure. Hypokalemic effect of the plant may increase the effect of the loop and thiazide diuretics |
|To treat depression, seasonal affective disorder, anxiety and insomnia, especially related to menopause ||Gliclazide (an antidiabetic drug)||Increases the apparent clearance of gliclazide |
|Carbamazepine, phenytoin and phenobarbital (antiepileptics)||Clinically significant interaction is unlikely, but |
|Alprazolam, midazolam, triazolam and quazepam (benzodiazepines)||Since the main compound hyperforin induces the enzyme CYP3A4, bioavailability may decrease [20, 57]|
|Indinavir (protease inhibitor)|
Nevirapine (nonnucleoside reverse transcriptase)
|May decrease the antiretroviral drugs and may lead to development of drug resistance [58, 59]|
|Cyclosporine, tacrolimus, (Immunosuppressants)||May decrease the blood levels and may lead the acute organ rejection in transplant patients [60, 61, 62]|
|Warfarin and phenprocoumon (anticoagulants)||May cause a moderate reduction in the anticoagulant effects of the drugs |
|Simvastatin and atorvastatin (antihyperlipidemic agents)||May observe the increasing serum level of total cholesterol [63, 64]|
|Nifedipine, verapamil (calcium channel blockers) and talinolol (a β-adrenoceptor blocker)||May decrease the bioavailability of drugs |
|Oral contraceptives||Associated with increased metabolism of ethinyl estradiol, norethindrone, and ketodesogestrel, and may cause bleeding and unwanted pregnancy [66, 67, 68, 69]|
|Carbamazepine (antiepileptic)||Should be considered a mild interaction between carbamazepine and |
|Sertraline, nefazodone (selective serotonin reuptake inhibitors)||May be occurred the symptoms of central serotonergic syndrome |
|Demulcent for bronchitis and coughs, and topically used for burns ||Anticoagulant or antiplatelet drugs||In the view of the thought that omega-3 fatty acids such as linolenic acid have antiplatelet effects, should be concerned about the possibility of prolonged bleeding |
|Adaptogenic ||Phenelzine (MAO inhibitor)||Additive nervous system effect of drug such as headache, tremor, sleeplessness and mania |
|Warfarin (anticoagulant)||INR may decrease by concomitant usage |
|Warfarin, heparin, aspirin, and NSAIDs||There is no clear data, but due to the antiplatelet components in |
|Caffeine||Possible additive stimulant effects |
|Anxiolytic, sedative, aphrodisiac||Barbiturates and benzodiazepines||Might potentiate the effects of central nervous system depressants |
|Alprazolam (benzodiazepine)||Risk of coma due to possible additive effect on GABA receptor |
|Levodopa||May reduce the efficacy due to possible dopaminergic antagonism |
|Acetaminophen||May enhance the risk of hepatotoxicity |
|Used for stress and insomnia as sedative and anxiolytic ||Barbiturates||Excessive sedation. The active component valerenic acid seems to likely to have the additive effect to phenobarbital |
|Other central nervous system depressants such as benzodiazepines and opioids||Possible additive sedative effects |
|Caffeine||Possible reverse effect to the sedative effect of Valerian |
|To reduce nausea and emesis induced by pregnancy, chemotherapy, and postoperative ileus ||NSAIDs||May reduce the platelet aggregation and enhance the bleeding tendency |
|Nifedipine||May potentiate the antiplatelet effects |
|Metronidazole||May increase the bioavailability |
|Glibenclamide (antidiabetic)||May reduce the blood glucose level |
12. Criteria for risk assessment of herbal products
There have been an increasing number of herbal products as food ingredients or supplements, which are a commercially important part of the health food market. Herbal products can range from whole foods (e.g., cranberry against urinary infections) to pharmaceutical-like preparations in unit dose form, such as tablets, capsules, or drops, and are thought to provide additional benefits beyond basic nutrition. The regulatory position on food supplements is uncertain (food or medicine?), and there is concern about the safety assurance of these products. Several cases of poisoning have been reported with herbal products. In some cases, these were caused by contamination with other plant species, but this is not always the case. In addition, toxic components (e.g., pyrrolizidine alkaloids) are accumulated at different concentrations in different parts of the source plant, and climatic and agronomic differences lead to great variability in the composition .
Therefore, it is not possible to provide a simple checklist of suitable tests to ensure the safety of herbal products. International guidelines are available for the safety assessment of herbal product and should be designed to cover all life stages to ensure a lifelong intake that can be consumed without significant health risk .
Information relating to herbal product identification, characterization, and standardization:
Botanical source: identity to family (geographic origin), genus, and species of source plant (with authority), and, if relevant, variety and chemotype; common names as well as part(s) of plant used. Evidence from previous human exposure through food or other sources (ethnobotanical and folk medicine studies).
Growing conditions: wild or cultivated plant (Good Agricultural Practice—GAP), site and time of harvest; stage of growth at harvest, post-harvest treatment (drying, fermentation, etc.), storage conditions, phytosanitary measures pre- and postharvest (including use of and limits for pesticides) are very important.
Raw material (fresh or dried plant materials): specifications according to standard reference (e.g., herbal Pharmacopoeias), identity tests (macroscopic, microscopic, FT-IR, TLC, GC, HPLC, etc.), quantitative tests (especially constituents related for efficacy and/or toxicity).
Process applied to starting material: preparation steps (e.g., separation, extraction processes, solvents), methods used, handling specific precautions; e.g., light/temperature sensitivity, oxidation, etc.
Botanical preparation: standardization criteria (markers: active constituents, other related components; plant extract ratio), specifications: levels and range for markers, physico-chemical properties of relevant components; stability, purity criteria by chain control or analysis; microbiological, mycotoxins, pesticides, and environmental contaminants. Nature and level of excipients; formulation methodology, storage conditions should have been specified.
End product: formulated product.
Specification of the product.
Extent of use and estimated intake (posology and method of administration).
Bioavailability of active principles.
Preclinical and clinical studies. Clinical data including variability of response, adverse effects reports, and contraindications .
13. Possible ways to reduce the toxic effects of herbal products
Natural products/compounds are unique remedies, but as Paracelsus (1493–1541) stated that all substances are poison and this is just the correct dose that makes them medicine. There are some rules in the literature that can be summarized as follows:
If the herbal remedy is not prescribed by a registered physician, it should be considered unsafe.
The label and expiration date of the herbal products should be checked for the seal of the regulatory authority.
If the herbal medicine is consumed with allopathic medicines, the doctor should be informed.
Herbal products should not be used with drugs possessing narrow therapeutic index such as cyclosporin, digoxin, theophylline, and warfarin.
Herbal products containing heavy metals such as arsenic, lead, and mercury should not be used.
Pregnant or breastfeeding mothers should be careful when using herbal remedies such as black cohosh, chamomile, sage, Dong Quai root, feverfew, ginger, kava kava, St. John’s wort, etc.
Excessive consumption of herbal/herbal medicine/natural products should be avoided and dosing instructions should be followed .
Herbal and traditional medicines are preferred as primary health care by three quarters of the world’s population. Therefore, it is crucial in drug research to investigate the effectiveness and adverse effects of herbal medicine, to identify the active compounds in medicinal plants and to detect contamination from poisonous plants or herbal mixtures. In 2013, the World Health Organization (WHO) published the WHO traditional medicine strategy (2014–2023). It aims to support the use of Traditional Medicine (TM) and/or Complementary and Alternative Medicine (CAM) to improve public health, including phytotherapy using of medicinal product (MP) and/or herbal medicinal product (HMP) for medical practice. The plan aims to increase the safety, efficacy, and quality of TM and/or CAM by expanding its knowledge base and providing guidance on regulatory and quality assurance standards (WHO, 2013). In 2016, the National Complementary and Integrative Health Center (NCCIH) published a strategic plan to explore complementary and integrative health science. This plan has been published to inform the public, healthcare professionals, and health policy makers, with evidence-based information about the usefulness and safety of complementary and integrative health interventions and their role in health care development. The plan uses key research to facilitate understanding of the biological effects, mechanisms of action, effectiveness, and clinical effects of complementary health approaches. Both the WHO and NCCIH plans aim to improve TM and CAM knowledge, including phytotherapy. Therefore, understanding herb-drug interactions and the molecular mechanisms involved in these processes is a way to guarantee safe use of MP and/or HMP. In addition, this can help therapeutic planning and healthcare professionals to recommend the best treatment strategy to use.
In this review, some critical issues are also discussed. The botanical identification and labeling of the plant material are important for preventing undesirable health problems. The changes in the scientific definitions of the plants in traditional medicine in time can cause unwanted or toxicologic effects by the usage of the wrong plant. The contamination of the plants with the environmental contaminants (microorganisms, fungal toxins such as aflatoxins, pesticides, and heavy metals), inappropriate preparation process, and interaction of traditional herbs by concomitant or consecutive usage also endanger the safety of herbal medicine for human health. What makes herbal medicine research valuable is that it has the chance to research harmful and toxic plants for developing pharmacologically and therapeutically worth remedies, and to develop medicinal plant combinations as safe and efficient herbal medicines. Standardization and strict control mechanisms are essential to maintain the high quality of herbal products and to prevent from the contaminations for the safety of patients .
The following guidelines can be suggested to minimalize the risk of herbal uses:
Should not be used in case of pregnancy or a possibility of pregnancy and to babies.
Should not be used when breast-feeding.
Should not be used as daily and in large amounts.
Should be bought from the pharmacies and only in case the plant names are stated on the packages and sealed by the Ministry of Health.
Do not believe it is useless if it is natural or it is harmless if it is natural .
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this chapter.
Shaikh AS, Thomas AB, Chitlange SS. Herb-drug interaction studies of herbs used in treatment of cardiovascular disorders—A narrative review of preclinical and clinical studies. Phytotherapy Research; 2020. DOI: 10.1002/ptr.6585
Kleter GA, Groot MJ, Poelman M, Kok EJ, Marvin HJP. Timely awareness and prevention of emerging chemical and biochemical risks in foods: Proposal for a strategy based on experience with recent cases. Food and Chemical Toxicology. 2009; 47(5):992-1008. DOI: 10.1016/j.fct.2008.08.021
Nudrat F, Naira N. Toxic effects as a result of herbal medicine intake. In: Larramendy M, editor. Toxicology-New Aspects to This Scientific Conundrum. Rijeka: Intechopen; 2016. DOI: 10.5772/64468
Brown AC. Kidney toxicity related to herbs and dietary supplements: Online table of case reports. Part 3 of 5 series. Food and Chemical Toxicology. 2017; 107(Pt A):502-519. DOI: 10.1016/j.fct.2016.07.024
Rasmussen CB, Glisson JK, Minor DS. Dietary supplements and hypertension: Potential benefits and precautions. The Journal of Clinical Hypertension. 2012; 14(7):467-471. DOI: 10.1111/j.1751-7176.2012.00642.x
Ernst E. Serious psychiatric and neurological adverse effects of herbal medicines—A systematic review. Acta Psychiatrica Scandinavica. 2003; 108(2):83-91. DOI: 10.1034/j.1600-0447.2003.00158.x
Chan TYK. Worldwide occurrence and investigations of contamination of herbal medicines by tropane alkaloids. Toxins. 2017; 9(9). DOI: 10.3390/toxins9090284
Wen B, Gorycki P. Bioactivation of herbal constituents: Mechanisms and toxicological relevance. Drug Metabolism Reviews. 2019; 51(4):453-497. DOI: 10.1080/03602532.2019.1655570
Bartnik M, Facey PC. Glycosides. In: Badal S, Delgoda R, editors. Pharmacognosy: Fundamentals, Applications and Strategy. London, UK: Elsevier Inc.; 2017. pp. 101-161. DOI: 10.1016/C2014-0-01794-7
Ernst E. Risks of herbal medicinal products. Pharmacoepidemiology and Drug Safety. 2004; 13(11):767-771. DOI: 10.1002/pds.1014
Chan TYK, Critchley JAJH. Usage and adverse effects of Chinese herbal medicines. Human & Experimental Toxicology. 1996; 15(1):5-12. DOI: 10.1177/096032719601500102
Tatli II. Plant/Herbs-Drugs-Herbal Products-Components-Nutrient Interactions. Postgraduate Education Course, Nutrition and Dietetics Department, Hacettepe University; 2013
Costache I-I, Miron A, Hăncianu M, Aursulesei V, Costache AD, Aprotosoaie AC. Pharmacokinetic interactions between cardiovascular medicines and plant products. Cardiovascular Therapeutics. 2019; 2019:1-19. DOI: 10.1155/2019/9402781
Fasinu PS, Rapp GK. Herbal interaction with chemotherapeutic drugs—A focus on linically significant findings. Frontiers in Oncology. 2019; 9:1356. DOI: 10.3389/fonc.2019.01356
Mazhar H, Foster BC, Necyk C, Gardiner PM, Harris CS, Robaey P. Natural health product-drug interaction causality assessment in pediatric adverse event reports associated with attention-deficit/hyperactivity disorder medication. Journal of Child and Adolescent Psychopharmacology. 2020; 30(1):38-47. DOI: 10.1089/cap.2019.0102
Shamsuddin N, Karuppannan M, Hafiz Wan Md Adnan WA, Farooqui M, Gnanasan S. Pattern of complementary and alternative medicine (CAM) use among patients with chronic kidney disease. Complementary Therapies in Clinical Practice. 2019; 37:86-92. DOI: 10.1016/j.ctcp.2019.09.003
Efferth T, Kaina B. Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Current Drug Metabolism. 2011; 12(10):989-996. DOI: 10.2174/138920011798062328
Gurley BJ, Tonsing-Carter A, Thomas SL, Fifer EK. Clinically relevant herb-micronutrient interactions: When botanicals, minerals, and vitamins collide. Advances in Nutrition. 2018; 9(4):524S-532S. DOI: 10.1093/advances/nmy029
Hou YN, Deng G, Mao JJ. Practical application of “about herbs” website: Herbs and dietary supplement use in oncology settings. The Cancer Journal. 2019; 25(5):357-366. DOI: 10.1097/ppo.0000000000000403
Williamson E, Driver S, Baxter K. Stockley’s Herbal Medicines Interactions. 1st ed. London: Pharmaceutical Press; 2009
Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Complementary Therapies in Clinical Practice. 2006; 12(4):236-241. DOI: 10.1016/j.ctcp.2006.06.002
Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: A case report. Neurosurgery. 1990; 26(5):880-882. DOI: 10.1097/00006123-199005000-00026
Burnham BE. Garlic as a possible risk for postoperative bleeding. Plastic and Reconstructive Surgery. 1995; 95(1):213. DOI: 10.1097/00006534-199501000-00060
Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clinical Infectious Diseases. 2002; 34(2):234-238. DOI: 10.1086/324351
Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. European Journal of Pharmaceutical Sciences. 2010; 41(5):729-735. DOI: 10.1016/j.ejps.2010.09.016
Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: An overview of mechanisms of action and clinical implications. Diabetology & Metabolic Syndrome. 2017; 9:59. DOI: 10.1186/s13098-017-0254-9
Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet. 1979; 1(8116):607. DOI: 10.1016/s0140-6736(79)91028-6
Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, et al. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiology, Biomarkers & Prevention. 1994; 3(2):155
Boudreau MD, Beland FA. An evaluation of the biological and toxicological properties of Aloe barbadensis(miller), Aloe vera. Journal of Environmental Science and Health Part C, Environmental Carcinogenesis & Ecotoxicology Reviews. 2006; 24(1):103-154. DOI: 10.1080/10590500600614303
Foster M, Hunter D, Samman S. Evaluation of the nutritional and metabolic effects of Aloe vera. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton, FL: CRC Press/Taylor & Francis; 2011
Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, Chokechaijaroenporn O. Antidiabetic activity of Aloe veraL. juice. I. Clinical trial in new cases of diabetes mellitus. Phytomedicine. 1996; 3(3):241-243. DOI: 10.1016/s0944-7113(96)80060-2
Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Archives of Internal Medicine. 1998; 158(20):2200-2211. DOI: 10.1001/archinte.158.20.2200
Abebe W. Herbal medication: Potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics. 2002; 27(6):391-401. DOI: 10.1046/j.1365-2710.2002.00444.x
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs. 2001; 61(15):2163-2175. DOI: 10.2165/00003495-200161150-00002
Kubota Y, Kobayashi K, Tanaka N, Nakamura K, Kunitomo M, Umegaki K, et al. Pretreatment with Ginkgo bilobaextract weakens the hypnosis action of phenobarbital and its plasma concentration in rats. The Journal of Pharmacy and Pharmacology. 2004; 56(3):401-405. DOI: 10.1211/0022357022836
Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo bilobaand ibuprofen. Atherosclerosis. 2003; 167(2):367. DOI: 10.1016/S0021-9150(03)00015-7
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo bilobaextract. The New England Journal of Medicine. 1997; 336(15):1108. DOI: 10.1056/nejm199704103361518
Matthews MK. Association of Ginkgo bilobawith intracerebral hemorrhage. Neurology. 1998; 50(6):1933-1934. DOI: 10.1212/wnl.50.6.1933
Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Safety. 1997; 17(5):342-356. DOI: 10.2165/00002018-199717050-00006
Shinozuka K, Umegaki K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J, et al. Feeding of Ginkgo bilobaextract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sciences. 2002; 70(23):2783-2792. DOI: 10.1016/S0024-3205(02)01530-8
Yoshioka M, Ohnishi N, Sone N, Egami S, Takara K, Yokoyama T, et al. Studies on interactions between functional foods or dietary supplements and medicines. III. Effects of Ginkgo bilobaleaf extract on the pharmacokinetics of nifedipine in rats. Biological & Pharmaceutical Bulletin. 2004; 27(12):2042-2045. DOI: 10.1248/bpb.27.2042
Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, et al. Effects of Ginkgo bilobaextract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. The Annals of Pharmacotherapy. 2009; 43(5):944-949. DOI: 10.1345/aph.1L656
Fan L, Mao XQ , Tao GY, Wang G, Jiang F, Chen Y, et al. Effect of Schisandra chinensisextract and Ginkgo bilobaextract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica. 2009; 39(3):249-254. DOI: 10.1080/00498250802687657
Ohnishi N, Kusuhara M, Yoshioka M, Kuroda K, Soga A, Nishikawa F, et al. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo bilobaleaf extract on the pharmacokinetics of diltiazem in rats. Biological & Pharmaceutical Bulletin. 2003; 26(9):1315-1320. DOI: 10.1248/bpb.26.1315
Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food and Chemical Toxicology. 2006; 44(9):1572-1578. DOI: 10.1016/j.fct.2006.04.008
Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo bilobaextract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Current Medical Research and Opinion. 2008; 24(2):591-599. DOI: 10.1185/030079908X260871
Zhao LZ, Huang M, Chen J, Ee PL, Chan E, Duan W, et al. Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Current Drug Metabolism. 2006; 7(6):577-587. DOI: 10.2174/138920006778017740
Tang J, Sun J, Zhang Y, Li L, Cui F, He Z. Herb–drug interactions: Effect of Ginkgo bilobaextract on the pharmacokinetics of theophylline in rats. Food and Chemical Toxicology. 2007; 45(12):2441-2445. DOI: 10.1016/j.fct.2007.05.023
Yin OQ , Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: Experience with Ginkgo bilobaand omeprazole. Pharmacogenetics. 2004; 14(12):841-850. DOI: 10.1097/00008571-200412000-00007
Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Wu J, Umegaki K. Ginkgo bilobaextract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sciences. 2004; 75(9):1113-1122. DOI: 10.1016/j.lfs.2004.02.020
Miman MC, Ozturan O, Iraz M, Erdem T, Olmez E. Amikacin ototoxicity enhanced by Ginkgo bilobaextract (EGb 761). Hearing Research. 2002; 169(1-2):121-129. DOI: 10.1016/s0378-5955(02)00385-4
Chen MF, Shimada F, Kato H, Yano S, Kanaoka M. Effect of glycyrrhizin on the pharmacokinetics of prednisolone following low dosage of prednisolone hemisuccinate. Endocrinologia Japonica. 1990; 37(3):331-341. DOI: 10.1507/endocrj1954.37.331
Chen MF, Shimada F, Kato H, Yano S, Kanaoka M. Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Endocrinologia Japonica. 1991; 38(2):167-174. DOI: 10.1507/endocrj1954.38.167
Teelucksingh S, Mackie ADR, Burt D. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet. 1990; 335(8697):1060-1063
Kageyama Y, Suzuki H, Saruta T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney. The Journal of Endocrinology. 1992; 135(1):147-152. DOI: 10.1677/joe.0.1350147
Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology. 2008; 153(7):1579-1586. DOI: 10.1038/sj.bjp.0707685
Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort ( Hypericum perforatum): An update on clinical observations. American Association of Pharmaceutical Scientists Journal. 2009; 11(4):710-727. DOI: 10.1208/s12248-009-9146-8
Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John’s wort. Lancet. 2000; 355(9203):547-548. DOI: 10.1016/S0140-6736(99)05712-8
de Maat MMR, Hoetelmans RMW, Mathôt RAA, van Gorp ECM, Meenhorst PL, Mulder JW, et al. Drug interaction between St John’s wort and nevirapine. AIDS. 2001; 15(3):420-421
Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum(St. John’s wort) after organ transplantation. American Journal of Kidney Diseases. 2001; 38(5):1105-1107. DOI: 10.1053/ajkd.2001.28617
Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John’s wort ( Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology. 2004; 44(1):89-94. DOI: 10.1177/0091270003261078
Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrology Dialysis Transplantation. 2003; 18(4):819-822. DOI: 10.1093/ndt/gfg002
Andrén L, Andreasson A, Eggertsen R. Interaction between a commercially available St John’s Wort product (Movina) and atorvastatin in patients with hypercholesterolemia. European Journal of Clinical Pharmacology. 2007; 63:913-916. DOI: 10.1007/s00228-007-0345-x
Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clinical Pharmacology and Therapeutics. 2001; 70(6):518-524. DOI: 10.1067/mcp.2001.120025
Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John’s wort and implication in drug development. Current Pharmaceutical Design. 2008; 14(17):1723-1742. DOI: 10.2174/138161208784746798
Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John’s Wort with oral contraceptives: Effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005; 71(6):402-408. DOI: 10.1016/j.contraception.2004.11.004
Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ , et al. The interaction between St John’s wort and an oral contraceptive. Clinical Pharmacology and Therapeutics. 2003; 74(6):525-535. DOI: 10.1016/j.clpt.2003.08.009
Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John’s wort with low-dose oral contraceptive therapy: A randomized controlled trial. British Journal of Clinical Pharmacology. 2003; 56(6):683-690. DOI: 10.1046/j.1365-2125.2003.02005.x
Schwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St. John’s wort despite hormonal contraception. British Journal of Clinical Pharmacology. 2003; 55(1):112-113. DOI: 10.1046/j.1365-2125.2003.01716.x
Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. Journal of Geriatric Psychiatry and Neurology. 1999; 12(1):7-10. DOI: 10.1177/089198879901200103
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: Nature of the evidence. The Annals of Pharmacotherapy. 2000; 34(12):1478-1482. DOI: 10.1345/aph.10031
Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava ( Piper methysticumForst. f.). Journal of Ethnopharmacology. 2004; 93(2):153-160. DOI: 10.1016/j.jep.2004.04.009
Shi S, Klotz U. Drug interactions with herbal medicines. Clinical Pharmacokinetics. 2012; 51(2):77-104. DOI: 10.2165/11597910-000000000-00000
Hendriks H, Bos R, Woerdenbag HJ, Koster AS. Central nervous depressant activity of valerenic acid in the mouse. Planta Medica. 1985; 51(1):28-31. DOI: 10.1055/s-2007-969384
Lien H-C, Sun WM, Chen Y-H, Kim H, Hasler W, Owyang C. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2003; 284(3):G481-G4G9. DOI: 10.1152/ajpgi.00164.2002
Young HY, Liao JC, Chang YS, Luo YL, Lu MC, Peng WH. Synergistic effect of ginger and nifedipine on human platelet aggregation: A study in hypertensive patients and normal volunteers. The American Journal of Chinese Medicine. 2006; 34(4):545-551. DOI: 10.1142/s0192415x06004089
Okonta JM, Uboh M, Obonga WO. Herb-drug interaction: A case study of effect of ginger on the pharmacokinetic of metronidazole in rabbit. Indian Journal of Pharmaceutical Sciences. 2008; 70(2):230-232. DOI: 10.4103/0250-474X.41462
Walker R. Criteria for risk assessment of botanical food supplements. Toxicology Letters. 2004; 149(1):187-195. DOI: 10.1016/j.toxlet.2004.03.001
Huxtable RJ. The myth of beneficent nature: The risks of herbal preparations. Annals of Internal Medicine. 1992; 117(2):165-166. DOI: 10.7326/0003-4819-117-2-165